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Abstract
 
We examined the effects of human immunodeficiency virus infection on the turnover of CD4
and CD8 T lymphocytes in 17 HIV-infected patients by 30 min in vivo pulse labeling with
bromodeoxyuridine (BrdU). The percentage of labeled CD4 and CD8 T lymphocytes was ini-
tially higher in lymph nodes than in blood. Labeled cells equilibrated between the two com-
partments within 24 h. Based on mathematical modeling of the dynamics of BrdU-labeled cells
in the blood, we identified rapidly and slowly proliferating subpopulations of CD4 and CD8 T
lymphocytes. The percentage, but not the decay rate, of labeled CD4 or CD8 cells in the rap-
idly proliferating pool correlated significantly with plasma HIV RNA levels for both CD4 (
 
r
 
 
 
 
 
0.77, 
 
P
 
 
 
  
 
0.001) and CD8 (
 
r
 
 
 
  
 
0.81, 
 
P
 
 
 
  
 
0.001) T cells. In six patients there was a geometric
mean decrease of greater than 2 logs in HIV levels within 2 to 6 mo after the initiation of
highly active antiretroviral therapy; this was associated with a significant decrease in the per-
centage (but not the decay rate) of labeled cells in the rapidly proliferating pool for both CD4
(
 
P
 
 
 
  
 
0.03) and CD8 (
 
P
 
 
 
  
 
0.001) T lymphocytes. Neither plasma viral levels nor therapy had
an effect on the decay rate constants or the percentage of labeled cells in the slowly proliferat-
ing pool. Monocyte production was inversely related to viral load (
 
r
 
 
 
   
 
0.56, 
 
P
 
 
 
  
 
0.003) and
increased with therapy (
 
P
 
 
 
  
 
0.01). These findings demonstrate that HIV does not impair CD4
T cell production but does increase CD4 and CD8 lymphocyte proliferation and death by in-
ducing entry into a rapidly proliferating subpopulation of cells.
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Introduction
 
Infection with HIV leads to a state of chronic immune acti-
vation and a progressive deterioration in immune function,
manifested most recognizably by a decline in CD4 T cell
number (1, 2). While early studies suggested that there was a
massive turnover of CD4 T cells that was being driven by
HIV-induced cell death, recent studies have identified a
 
more modest, 
 
 
 
two- to sixfold, increase in the fraction of
proliferating CD4 and CD8 T cells when compared with
individuals without HIV infection (3–12). The mechanisms
leading to this increase in proliferation have been ill defined.
Moreover, the impact of suppression of viral replication on
lymphocyte turnover has remained controversial, with some
studies suggesting an initial increase in proliferation after
suppression, while others have found an immediate and per-
sistent decrease in proliferation following initiation of highly
 
active antiretroviral therapy (HAART)
 
*
 
 (6, 7, 9, 10, 13).
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Measurement of lymphocyte turnover in humans has
until recently depended on indirect markers, such as
changes in cell number in the periphery following ther-
apy, differences in telomere length, Ki67 labeling, or
tracking of chromosomal abnormalities (1–10, 12, 14). Di-
rect measures of cell replication in vivo, which can pro-
vide more reliable information regarding cell turnover and
can provide longitudinal information about proliferating
cells, have only recently been applied to the study of lym-
phocytes, using deuterium or bromodeoxyuridine (BrdU)
as a marker (6, 9, 10). Labeling of newly synthesized DNA
with deuterium provides a method for directly measuring
turnover in a population of cells, although individual cells
or minority populations cannot be easily studied. BrdU is
a thymidine analogue that is incorporated into the DNA
of replicating cells; incorporated BrdU can be detected us-
ing a monoclonal antibody (15, 16). BrdU has been used
to measure lymphocyte proliferation in vivo in animals
and ex vivo in humans (6, 13, 17–19). BrdU has also been
extensively used as an in vivo labeling agent to measure
proliferation of tumor cells in patients with malignancies;
in this setting BrdU administration has been associated
with no major toxicities (20–22). In vivo labeling with
BrdU provides the opportunity not only to identify prolif-
erating populations of cells by flow cytometry, but also to
determine their decay kinetics by following proliferating
cells longitudinally.
Here we show by in vivo labeling with BrdU and math-
ematical modeling that while there is one population of
monocytes, there are at least two dynamically distinct sub-
populations of CD4 and CD8 T cells, a rapidly and a
slowly proliferating subpopulation. While the size of the
rapidly proliferating pools of both CD4 and CD8 T cells
directly correlated with plasma viral load, viral load had no
impact on the size of the slowly proliferating population.
HAART decreased the size of the rapidly proliferating sub-
population of both CD4 and CD8 T cells without impact-
ing the slowly proliferating subpopulation.
 
Materials and Methods
 
Patients.
 
Patients with HIV infection and no major clinical
or laboratory abnormalities were enrolled in the study. Patients
who were pregnant or breast feeding, or receiving 5 fluorouracil
were excluded from participation. Patients were selected to span
the spectrum of stages of HIV infection. While BrdU has been
used in cancer patients as a marker for rates of cell turnover
without any observed toxicities, it has been shown to be terato-
genic in animal models. For this reason the risk benefit ratio was
felt by ourselves and the institutional review board to preclude it
use in healthy volunteers. Participants in the study were coun-
seled to practice effective contraception. The study was ap-
proved by the National Institute of Allergy and Infectious Dis-
eases institutional review board, and all patients provided written
informed consent.
 
BrdU Infusion and Flow Cytometry.
 
BrdU (NEOMARK-
BU
 
®
 
) was supplied by NeoPharm through the National Cancer
Institute, and infused at a dose of 200 mg/m
 
2
 
 over 30 min (22).
For analysis of BrdU incorporation, 10 ml of EDTA treated
 
whole blood was analyzed for surface markers and incorporated
BrdU by flow cytometry as described previously (6). After stain-
ing for surface markers (23) and fixation in 1% paraformalde-
hyde/1% Tween 20, cells were treated with DNase 1 to expose
incorporated BrdU, stained with FITC-labeled anti-BrdU mono-
clonal antibody (Becton Dickinson), and analyzed by flow cy-
tometry. Lymph node biopsy samples were pushed through a
mesh screen to obtain a single cell suspension and then processed
as for whole blood. 20,000 to 50,000 gated events were collected
for most samples; a minimum of 5,000 gated events were col-
lected when the gated cell count was low.
Ki67 staining of cryopreserved peripheral mononuclear cells
was performed as described, using a phycoerythrin-labeled anti-
Ki67 antibody (clone B56; BD PharMingen; reference 2).
 
Immunohistochemistry.
 
Lymph node sections were double
stained with an anti-BrdU monoclonal antibody (1:500 dilution,
MO744; Dako) and an anti-CD8 monoclonal antibody (1:400
dilution, NCL-CD8–4B11, Novocastra; Vector Laboratories).
Slides were pretreated with 4N hydrochloric acid for 20 min at
37
 
 
 
C, rinsed in pH 7.6 boric acid–borate buffer and then treated
with prewarmed 0.01% trypsin for 3 min at 37
 
 
 
C before incuba-
tion with the anti-BrdU antibody. The Vectastain Mouse Elite
ABC (avidin-biotin complex) kit (Vector Laboratories) using the
rapid staining procedure was used for the secondary antibody and
diaminobenzidine (DAB) was the chromagen. Subsequently slides
were pretreated by microwaving in 1 mM EDTA, pH 8, then in-
cubated with the anti-CD8 antibody. The secondary antibody
was affinity purified, peroxidase labeled goat anti-mouse IgG, hu-
man serum absorbed, and the chromagen was HistoMark True
Blue
 
®
 
 (Kirkegaard and Perry Laboratories).
 
Modeling.
 
The data were fitted to the differential equations
with the computer program Scientist (MicroMath). Statistical
analysis was performed by using the program Statistica (Statsoft).
 
Results
 
Patient Characteristics.
 
17 patients (16 male; mean age,
45 yr) enrolled in the study (Table I). The mean CD4
count at enrollment was 349 cells/mm
 
3
 
 (range, 59 to 888
cells/mm
 
3
 
) and the geometric mean viral load was 3.72
log
 
10
 
 copies/ml (range, 
 
 
 
1.70 to 5.55 log
 
10
 
 copies/ml).
Six patients (five males) with a mean age of 43 yr received
two infusions of BrdU. At the time of the first infusion,
the mean CD4 count was 380 cells/mm
 
3
 
 (range, 59 to
888 cells/mm
 
3
 
) and the geometric mean viral load was
4.42 log
 
10
 
 copies/ml (range, 3.56 to 4.96 log
 
10
 
 copies/ml).
At the first infusion four patients were receiving no anti-
retroviral therapy and two were receiving ineffective
therapy (viral loads of 4.17 and 4.30 log
 
10
 
 copies/ml). At
the time of the second infusion the mean CD4 count was
556 (range, 174 to 1,116) and the geometric mean viral
load was 2.05 log
 
10
 
 copies/ml (range, 
 
 
 
1.70 to 2.96 log
 
10
 
copies/ml).
 
BrdU Incorporation Can Be Detected by Flow Cytometry.
 
After a 30-min infusion of BrdU, incorporation into DNA
was easily detected by flow cytometry in lymphocytes as
well as monocytes (Fig. 1). The percent incorporation and
rate of appearance in the periphery varied depending on
the cell type. For monocytes, there was limited appearance
of labeled cells in the periphery over the first 24 h, after 
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which there was a rapid increase to a peak in labeling at day
2–4, in the range of 30 to 45% (Figs. 1 and 2 A). This was
followed by a rapid decline so that no label was detectable
after day 10–14 (Fig. 2 A). A previous study using in vivo
labeling with tritiated thymidine to characterize monocyte
kinetics in healthy men showed a very similar pattern both
in the timing and the peak of labeling as seen in the current
study, thus providing verification of the validity of the
BrdU labeling method (24).
Lymphocytes showed a distinctly different pattern of la-
beling. CD4 and CD8 lymphocytes with incorporated
BrdU were detected in the periphery within 6 h of com-
pletion of the infusion, and gradually increased thereafter,
to a peak in the range of 0.5 to 5%, generally at days 2 to 4
after the infusion, with a subsequent gradual decline (Fig. 2
A); labeled cells could still be detected for months. Peak la-
beling correlated with the percent of Ki67 positive cells for
both CD4 cells (
 
r
 
 
 
  
 
0.63, 
 
P
 
 
 
  
 
0.001) and CD8 cells (
 
r 
 
 
 
0.57, 
 
P
 
 
 
  
 
0.006). Peripheral blood B lymphocytes showed
a similar pattern to T lymphocytes, but with greater vari-
ability to peak labeling (1 to 17 d) and a generally lower
peak of incorporation (Fig. 2 A).
 
Rapid Equilibration of Proliferating Cells between Lymphoid
Tissue and Blood.
 
Because proliferation of lymphocytes
occurs primarily in secondary lymphoid organs, BrdU in-
corporation by lymphocytes residing in lymph nodes was
examined for 10 patients who underwent lymph node bi-
opsy at various time points after a BrdU infusion. At 6 h af-
ter the 30-min BrdU pulse, labeling was 
 
 
 
two- to three-
fold greater in the lymph node compared with the blood
for both CD4 and CD8 cells, but by 24 h the percent posi-
tive cells were approximately equivalent in the two com-
partments (Fig. 2 B). B cells, however, showed substantially
higher (
 
 
 
6-fold) labeling in the lymph node compared
with the blood at all the time points measured (Fig. 2 B).
Immunohistochemical staining of lymph node biopsies
showed a high proportion of proliferating cells in the lym-
phoid follicles; these cells included CD4 and CD8 cells, in
addition to B cells (Fig. 2 C). Thus, an equilibrium be-
tween lymph nodes and blood is rapidly established (within
24 h) for CD4 and CD8 cells (but not for B cells) that have
recently proliferated, and measurement of BrdU incorpora-
tion in peripheral CD4 and CD8 cells after 24 h provides
an accurate reflection of the proportion of BrdU positive
CD4 and CD8 cells in lymphoid tissues.
 
Identification of Rapidly and Slowly Proliferating Subpopula-
tions of CD4 and CD8 T Lymphocytes.
 
To investigate the
relationships between lymphocyte turnover and immuno-
logic or virologic parameters, 17 patients (Table I) received
a BrdU infusion; six of these patients received a second in-
 
Table I.
 
Baseline Characteristics of the Patients
 
First BrdU infusion Second BrdU infusion
Pt. 
no. Age
Antiretrovirals at the
time of infusion
CD4 no.
(cells/mm
 
3
 
)
Plasma HIV load
(Log
 
10
 
 copies/ml)
 
a
 
Antiretrovirals at the
time of infusion
CD4 no.
(cells/mm
 
3
 
)
Plasma HIV load
(Log
 
10
 
 copies/ml)
 
a
 
1 43 Rit/Ind/Sta/Lam
 
b
 
99 5.08 ND
2 49 None 134 5.00 ND
3 45 None 609 4.71 ND
4 57 Saq/Nel/Sta/Lam 247 3.01 ND
5 54 None 82 5.55 ND
6 41 Nel/Sta/Lam 99 3.16 ND
7 43 Ind/Nev/Sta/Lam 330 1.69 ND
8 34 Ind/Sta/Lam 551 2.62 ND
9 51 Ind/Zid/Lam 561 1.69 ND
10 59 None 499 2.51 ND
11 42 Nel/Del/Sta/Lam 448 1.75 ND
12 39 None 888 3.56 Ind/Efa/Sta/Lam 1,116 1.69
13 40 None 280 4.96 Rit/Saq/Nev/Zid/Lam 384 2.56
14 40 Nel/Nev/Sta/Did 169 4.31 Amp/Nel/Efa/Aba 174 1.69
15 36 None 442 4.95 Ind/Nev/Sta/Lam 857 1.69
16 48 None 443 4.28 Ind/Nev/Sta/Lam 574 1.69
17 52 Amp/Rit/Efa/Did/Aba 59 4.45 Lop/Rit/Ind/Sta/Lam 232 2.96
Mean 45 349 3.72 556 2.05
 
a
 
Values below 1.70 (log
 
10
 
 50 copies/ml), the detect limits of the assay, were assigned a value of 1.69 (log
 
10
 
 49 copies/ml).
 
b
 
Rit, ritonavir; Ind, Indinavir; Nel, Nelfinavir; Saq, Saquinavir; Amp, Amprenavir; Lop, Lopinavir; Nev, Nevirapine; Efa, Efavirenz; Del, Delavir-
dine; Zid, Zidovudine; Sta, Stavudine; Lam, Lamivudine; Did, Didanosine; Aba, abacavir; ND, second infusion not done. 
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fusion 8 to 26 wk after starting HAART. Data from a
total of 23 infusions were available for analysis. While
HIV-negative patients were not enrolled in this study,
data from ourselves and others using the technique of in
vivo labeling with deuterium have demonstrated lower
rates of T cell turnover in healthy volunteers compared
with HIV-infected patients (9, 10). In a limited number
of HIV infected patients both deuterium and BrdU la-
beling have been employed, with similar results (data
not shown). The two methodologies complement each
other: with deuterium one can label over a longer pe-
riod of time and thus reach higher peak levels of incor-
poration, while BrdU labeling allows for more frequent
and more detailed analyses of lymphocyte subpopula-
tions.
To describe the kinetics of BrdU labeled cells we con-
structed a semi-empirical equation based on the following
observations and considerations. The time-dependent de-
cay in the concentration of the labeled T cells after the
peak of labeling could not be represented by a single expo-
nential function. For most of the infusions (19 for CD4
cells and 16 for CD8 cells), the decay consisted of two
 
phases with significantly different slopes (using a logarith-
mic scale; Fig. 3). For patients who were followed for
longer times (longer than 30–50 d) a third phase with a
slope close to zero was also observed (Fig. 3). These find-
ings suggested the existence of at least two different sub-
populations of cells each decaying with its own rate con-
stant 
 
d
 
. The decay of these two populations could be
described by the following equations: 
 
L
 
 
 
  
 
L
 
1
 
 
 
L
 
2
 
; d
 
L
 
i
 
/
d
 
t
 
 
 
 
 
 
 
 
 
d
 
i
 
*
 
L
 
i
 
, where i   1,2, represents the two different
subpopulations, L is the fraction of labeled lymphocytes in
the blood, and t denotes time.
The final equation reads: dLi/dt   si*U-di*Li, i   1,2,
where U is a unit function equal to 1 at t   T and 0 at t  
T, T being the time required to reach the maximum con-
centration of labeled cells in the blood. The rate constant d
(units of inverse time) reflects cell death, delabeling and/or
redistribution outside of the blood/lymphatic system; the
source s (units: fraction of labeled cells entering the blood
per unit time) is a complex function of cell proliferation
and redistribution and is approximately proportional to cell
proliferation (percentage of BrdU-labeled CD4 or CD8
cells) in the lymphoid tissue.
Figure 1. Flow cytometry profiles demonstrating BrdU incorporation by lymphocytes and monocytes for a representative patient. BrdU incorporation
is shown along the X axis and cell surface markers are shown along the Y axis, as indicated. The percentage in the top right quadrant indicates the percent
of double-positive cells. Results are shown for days 1, 3, and 8 after the BrdU infusion for blood, and day 1 for lymph node. Gating for CD4  and CD8 
cells was based on light scatter together with positive staining for CD3.1735 Kovacs et al.
In developing this semi-empirical model, we assumed
that the lymphoid tissue serves as an effective source of la-
beled cells that are distributed to the blood until equilibra-
tion is reached, at which point the effective source ceases
to affect changes in the concentration of labeled cells. Be-
cause the percentage of labeled cells in the blood was ap-
proximately the same as in the lymph nodes after about
one day, we have assumed that the same time dependence
holds in both compartments after the peak labeling. Prior
to this time, an equilibration between blood and lymphoid
tissue has not yet been established, and the time depen-
dence of the labeled cells in the two compartments will
differ. The higher proportion of labeled cells in the lymph
nodes immediately after labeling (Fig. 2 B) suggests an ini-
tial redistribution of cells from the lymphoid tissue to the
blood. However, because of lack of longitudinal data for
the lymphoid tissue in individual patients and the limited
number (2–4) of time points for the blood during this early
period, it is not possible to use complex functions for data
fitting. Therefore, we selected a simple linear dependence
on time.
The fraction of labeled cells for each subpopulation at t  
T in the lymphoid tissue, Ni, is approximately equal to that
in the blood and proportional to si as well as to the fraction
ni at the time of labeling: ni   Ni/ki. For rapidly expanding
cell populations, e.g., in clonal expansions, the coefficient of
proportionality k is  2–4 based on the experimental data
for the lymphoid tissue at t   6 h and 24 h. The fraction of
the total number of cells (labeled and unlabeled) in the first
subpopulation f1 with respect to the total number of the
cells in the two subpopulations (but not all cells) is approxi-
mately equal to (n1/d1)/(n1/d1   n2/d2), and f2   1-f1, re-
spectively. However, as the constant d is an effective mea-
sure of death, delabeling and redistribution to nonlymphoid
tissue this estimate for the fraction of total cells should be
used with caution. We also tested other relatively simple
Figure 2. (A) Kinetics of BrdU labeled lymphocytes and monocytes in the blood. Days following the BrdU infusion are shown along the X axis, and
percent BrdU-positive cells along the Y axis, which is shown in log scale to illustrate the kinetic differences between monocytes and lymphocytes. Re-
sults represent the geometric mean (  SD) for the first infusion for all 17 patients during the first 30 d. Symbols are as follows: CD4  cells, blue triangles;
CD8  cells, red squares; B cells, green diamonds; monocytes, black circles. (B) BrdU incorporation by lymph node lymphocytes compared with blood
lymphocytes. Nine patients underwent lymph node biopsy 6 h to 3 d after BrdU infusion; two patients had a second biopsy after a second BrdU infusion.
Each dot represents the ratio of percent BrdU incorporation by lymph node CD4 (blue triangles), CD8 (red squares), or B (green diamonds) lymphocytes
to percent BrdU incorporation by that cell in the blood. The bar represents the mean for the indicated time point. The dashed line indicates a ratio of 1.
Results are shown in log scale. A single patient underwent lymph node biopsy at day 10 and showed ratios of 3.5, 1.4, and 0.3 for CD4, CD8, and B
cells, respectively. (C) Immunohistochemical staining of a lymph node biopsy obtained 6 h after a BrdU infusion. CD8 cells are stained blue. Cells that
incorporated BrdU are stained brown. Low power view (100 , top) demonstrates that the majority of BrdU-positive cells are localized to secondary fol-
licles. High power view (400 , bottom) demonstrates that many of the BrdU-positive cells in the follicle are also CD8 positive (arrows).1736 T Lymphocyte Turnover in HIV Infection
models and obtained essentially the same results; more com-
plex models including our previous model based on the ex-
istence of distinct cell subpopulations (25) can be reduced to
the simple model under some assumptions but are difficult
to fit with a unique set of parameters due to the limited
number of experimental points.
To analyze the changes in the monocyte population, we
used an equation similar to the one described above for
lymphocytes with the important difference that it takes into
account the maturation stage in the bone marrow, the lack
of significant recirculation of the monocytes and the rela-
tively homogeneous nature of the monocyte population
reflected in the observed one exponential decay of the frac-
tion of labeled cells in the blood (Fig. 2): dM/dt   s*U  
Figure 3. (A) Comparison of experimental data with modeling of the kinetics of BrdU incorporation by T lymphocytes and monocytes for a represen-
tative patient. The continuous lines represent fitting of the experimental data (black diamonds) by the model equations. For this patient, d1   0.29, 0.90,
1.27 d 1; d2   0.017, 0.042, 0 d 1; s1   0.033, 0.027, 0.48 d 1, s2   0.006, 0.004, 0.000 d 1, T   1.3, 1.8, 3.6 d; L01   L02   0, 0, 0; Ti   0, 0, 0.21 d,
for CD4 T cells, CD8 T cells and monocytes, respectively. L01 and L02 are the initial values (t   0) for L1 and L2, respectively. Inset shows the maturation
delay of monocytes in linear scale. (B) Comparison of experimental data with modeling of the kinetics of BrdU incorporation by T lymphocytes and
monocytes for all patients. The data for individual patients were normalized, assigning a value of 1 to the maximal fraction of labeled cells. The arithmetic
mean of the normalized values for all patients (black diamonds) are presented in logarithmic scale as a function of time. The continuous lines represent fit-
ting of the experimental data by the model equations with d1   0.36, 0.59, 0.61 d 1; d2   0.045, 0.060, 0 d 1; s1   0.33, 0.26, 0.72 d 1, s2   0.19, 0.25,
0 d 1, T   2, 2, 3 d; L01   0.13, 0.14, 0; L02   0, 0, 0; Ti   0, 0, 0.24 d, for CD4 T cells, CD8 T cells and monocytes, respectively. Here the values of s
were normalized to the maximal fraction of labeled cells Lm and are approximately equal to s/Lm. The lines denoted by 1 and 2 represent the model so-
lution for the rapidly and slowly proliferating subpopulations, respectively. The insets for T cells show data for patients who were followed for longer
than 30 d and exhibited a third slope (denoted by 3) in logarithmic scale (d3   0.094   10 2, 0.19   10 2 day 1; s3   0.040, 0.073 d 1 for CD4 T and
CD8 T cells, respectively). The inset for monocytes shows their maturation delay. Each data point represents the mean for all the patients who were seen
on a given day (relative to the infusion); this ranged from 21 patients for the earlier time points to one to four patients, especially for the later time points.
Error bars represent 1 standard deviation. (C) Relationship between s1 and the logarithm of the HIV RNA blood plasma concentration. A positive cor-
relation was noted for the rapidly proliferating T cell subpopulation (s1) for CD4 and CD8 T cells while a negative correlation was noted for the rate of
monocyte production (s). The HIV concentration below the limit of detection was set at 49 copies per ml. Individual results are shown by black dia-
monds. The regression lines and the 95% confidence intervals are shown with continuous and broken lines, respectively.1737 Kovacs et al.
d*M, where M is the fraction of labeled monocytes in the
blood;  s is a source of labeled monocytes entering the
blood; U is a function equal to zero between time 0 and
the maturation delay T1, is equal to 1 for the subsequent
time interval T, and is zero at times t   T1   T.
Fig. 3 A illustrates the fitting of the data to these models
for CD4 cells, CD8 cells, and monocytes, for one patient.
The two-phase kinetics of BrdU delabeling for CD4 and
CD8 cells using the entire dataset is illustrated in Fig. 3 B.
For the study group as a whole, the rapidly proliferating sub-
population of cells had a half-life (0.69/d) of 1.9 d for CD4
cells and 1.7 d for CD8 cells, while for the slowly proliferat-
ing subpopulation of cells, the respective half-lives were 20
and 17 d. These values represent minimal estimates because
of the possible effects of redistribution and delabeling.
Plasma Viral Load Correlates with the Size of the Rapidly
Proliferating Population of CD4 and CD8 Lymphocytes. To
characterize the factors driving lymphocyte turnover, we
examined the relationships between log plasma HIV RNA
(log HIV), CD4 cell number, or CD8 cell number at the
time of infusion, and fraction of labeled cells, N, source s,
and the decay constant, d, for the rapidly and slowly prolif-
erating subpopulation of cells. As shown in Table II and
Fig. 3 C, there was a significant association between log
HIV and s1 for both CD4 (r   0.77, P   0.001) and CD8
cells (r   0.81, P   0.001) (similarly for N1). There were
no significant associations between log HIV and s2 (simi-
larly for N2) or either of the decay constants. There was a
negative correlation between baseline CD4 and CD4 (but
not CD8) s1 (r    0.55, P   0.006) and s2 (r    0.58,
P   0.04), and between baseline CD8 and CD8 s2 (r  
 0.45, P   0.04).
Decrease in the Size of the Rapidly Proliferating Population
After Effective Antiretroviral Therapy. These data suggest
that HIV, either directly or indirectly, is expanding the
size of the pool of rapidly proliferating cells, and conse-
quently (as these short-lived cells represent a larger propor-
tion of the population) accelerating the overall decay (and
at steady state, death) rate for CD4 and CD8 cells; how-
ever, once cells have entered this pool, their turnover or
decay rate is not dependent on HIV. Based upon this one
would predict that control of HIV replication by HAART
should result in a decrease in the size of this rapidly prolif-
erating subpopulation, but not in the decay rate of this
subpopulation. To address this directly, we compared the
various parameters for six patients after two BrdU infu-
sions: before, and again 2 to 6 mo after successful HAART
therapy (Fig. 4, and Table III). This period between infu-
sions was chosen to coincide with the time-frame used in
two reports suggesting a HAART-related increase in CD4
cell proliferation (7, 9). Contrary to these prior reports, a
statistically significant, approximately fourfold decrease in
the size of the rapidly proliferating pool (s1) was seen for
both CD4 cells and CD8 cells. No significant change was
seen in the size of the slowly proliferating pool (s2) of ei-
ther CD4 or CD8 cells or in the decay constants (d1, d2)
for either subpopulation.
In contrast to lymphocytes, for monocytes there was a
significant inverse relationship between the production of
new cells (s) and log HIV (r    0.56, P   .003; Fig. 3 C).
No correlation was seen between the decay rate (d) for the
monocyte pool and log HIV (Table II). Thus, viral repli-
cation impacts monocytes and T lymphocytes differently.
HIV infection leads to an increase in the rate of T lym-
phocyte production, but to an overall decrease in the rate
of monocyte production. This may reflect the differences
between a cell population maintained by peripheral ex-
pansion and one maintained by stem cell differentiation.
After HAART therapy, a significant increase in s for
monocytes was seen (Table III), suggesting improved pro-
genitor cell function as a consequence of control of viral
replication.
Discussion
This study provides a new framework for understanding
the impact of HIV on cell turnover. The direct relationship
between the size of the rapidly proliferating pool (s1) and
Table II. Differential Effect of HIV on the Dynamics of T Cell Subpopulations and Monocytes
CD4 CD8 Monocytes
Mean SD rP Mean SD rP Mean SD rP
d1 (day 1) 0.37 0.26 0.29 NS 0.41 0.26  0.10 NS 0.80 0.36  0.21 NS
d2 (day 1) 0.036 0.032 0.25 NS 0.041 0.039 0.14 NS NA NA NA NA
s1 (day 1) 0.016 0.012 0.77  0.001 0.011 0.010 0.81  0.001 0.44 0.13  0.56 0.003
s2 (day 1) 0.009 0.010 0.28 NS 0.005 0.004  0.05 NS NA NA NA NA
Shown are the mean   SD, of the calculated source (s) and the decay constant (d) for the two subpopulations of cells for lymphocytes and the single
population for monocytes for 23 BrdU infusions (22 data sets for monocytes and CD8 T cells) in 17 patients as well as the correlation (Pearson
correlation coefficient r) between d or s and log plasma viral RNA at the time of the infusion and the statistical significance of this correlation (P). NS,
not significant (P   0.05). One patient with unusually high (about one order of magnitude higher than the average, statistically an outlier) CD8 T cell
turnover was excluded from the analysis. The inclusion of this patient decreases the correlation of s1 with HIV (r   0.64) but it is still highly statistically
significant (P   0.002). The correlations were approximately the same when analyzing only the first infusion for all 17 patients. NA, not applicable.1738 T Lymphocyte Turnover in HIV Infection
viral load, together with the decrease in s1 seen after control
of viral replication, for both CD4 and CD8 cells, demon-
strates that a major effect of ongoing HIV replication is to
drive a shift of both CD4 and CD8 cells from a slowly turn-
ing over compartment to one rapidly turning over. This
shift cannot be driven exclusively by HIV-mediated cyto-
pathicity however, as it is seen in both CD4 and CD8 T
cells. A more plausible explanation is that this shift is due to
immune activation of both populations, either directly in
response to antigen (HIV or other pathogens) or indirectly,
through induction of inflammatory mediators in lymphoid
tissue that leads to bystander activation (2, 26).
Figure 4. Change in BrdU incorporation by CD4 (top)
and CD8 (bottom) cells for a single patient after 12 wk of
HAART. Percent of cells with incorporated BrdU before
HAART are shown in diamonds, and 12 wk after therapy
with HAART in triangles. CD4 counts and viral load at
the time of the first infusion were 888 cells/mm3 and
3,649 HIV copies/ml, and at the time of the second infu-
sion were 1,116 cells/mm3 and  50 copies/ml, respec-
tively. Inset shows the percent of lymph node CD4 or
CD8 cells that were BrdU positive 6 h after the first (dia-
mond) or second (triangle) infusion. The continuous lines
represent fitting of the experimental data by the model
equations before/after treatment: d1   0.23/0.30, 0.38/
0.38 d 1;  d2    0.013/0.036, 0.049/0.020 d 1;  s1   
0.019/0.0027, 0.013/0.001, s2   0.001/0.003, 0.0057/
0.0016;  T    2.43/1.45, 2.36/2.0 d; L01    0.0035/
0.0017, 0.0/0.0012; L02   0/0, 0/0; for CD4 T cells and
CD8 T cells, respectively.
Table III. Differential Effect of HAART on the Dynamics of T Cell Subpopulations and Monocytes
CD4 CD8 Monocytes
Pre-therapy Post-therapy Pre-therapy Post-therapy Pre-therapy Post-therapy
Mean SD Mean SD P Mean SD Mean SD P Mean SD Mean SD P
d1 (day 1) 0.25 0.18 0.36 0.13 NS 0.40 0.19 0.38 0.13 NS 0.78 0.26 0.93 0.45 NS
d2 (day 1) 0.028 0.020 0.034 0.028 NS 0.063 0.063 0.033 0.014 NS NA NA NA NA NA
s1 (day 1) 0.024 0.014 0.006 0.003 0.03 0.020 0.007 0.005 0.005  0.001 0.38 0.12 0.55 0.11 0.01
s2 (day 1) 0.011 0.015 0.011 0.009 NS 0.007 0.006 0.006 0.004 NS NA NA NA NA NA
Shown are the mean   SD, of the calculated source (s) and the decay constant (d) for the two subpopulations of cells for lymphocytes and the single
population for monocytes for six patients who received two BrdU infusions, the first prior to HAART therapy (Pre-therapy) and the second 2 to 6
mo after initiation of HAART therapy (Post-therapy). Statistical significance (P) is for comparison of pre- and post-therapy values by t test for
dependent samples. NS, not significant (P   0.05). One patient with unusually high (about one order of magnitude higher than the average) CD8
T cell turnover was excluded from the analysis (see the legend of Table 2). NA, not applicable.1739 Kovacs et al.
Within the limits of this methodology, HIV replication
has no direct overall effect on the disappearance rate (death,
proliferation, and trafficking, but in steady-state ultimately
death) of the individual compartments, including the rap-
idly decaying compartment, which must therefore be de-
termined by other biological effects (e. g. mode of activa-
tion, expression of surface receptors, cytokine milieu).
Thus, entry into the rapidly proliferating pool is driven by
HIV, but once the cell enters this pool, its fate is not de-
pendent on HIV.
What cells do the two subpopulations represent? The
rapidly proliferating pool accounts for   1–10% of the
proliferating populations of both CD4 and CD8 cells in pa-
tients with low viral loads, but increases to  10–40% of
these populations in patients with the highest viral loads.
Preliminary results suggest that this subpopulation primarily
represents an expansion of activated memory or effector
cells that have a high turnover rate, many of which may
undergo programmed cell death after activation (25). The
slowly proliferating pool likely represents naive or long-
term memory cells that have a primary surveillance role
and are replicating via homeostatic mechanisms. The previ-
ously reported declines in both CD4 and CD8 naive cells
that occur with progressive HIV infection (27, 28) may
thus result from a relative shift of these cells to the rapidly
proliferating pool, without an increase in homeostatic pro-
liferation or replenishment via the thymus. Ongoing stud-
ies using additional markers for naive and memory cells as
well as activation markers should further clarify the pheno-
typic characteristics of the two populations.
Effective treatment of HIV infection with HAART re-
sults in a decrease in the size of the rapidly proliferating
pool, but has no effect on the decay constant of this pool.
Equally important, suppression of HIV replication by
HAART therapy does not lead to a change in any of the
kinetic parameters (s2, n2, or d2) of the slowly proliferating
pool. Thus there is no evidence suggesting that HIV is
suppressing production of lymphocytes (either CD4 or
CD8 cells), or that treatment leads to an increase in pro-
duction of either the rapidly or slowly proliferating sub-
population of T lymphocytes. The data presented here re-
garding the relationship between HIV treatment and T
cell production are the opposite of what has been previ-
ously published using deuterium labeling (9, 10). In these
nonlongitudinal studies the fractional replacement of CD4
cells was found to be significantly higher in five patients
after 12 wk of successful HAART when compared with a
separate cohort of seven patients with uncontrolled vire-
mia (9, 10). Our results are consistent with one study using
Ki67 staining as a marker of proliferation (2), but not an-
other that through extrapolation attempted to quantitate
the total number of proliferating cells in the entire lym-
phocyte pool (7).
However, consistent with other studies (29), our data do
suggest that HIV is suppressing bone marrow function.
HIV levels are inversely correlated with rates of monocyte
production (s), and HAART therapy is associated with a
significant increase in monocyte production. The effects of
HIV on different cell populations are presumably depen-
dent on multiple factors related to the intrinsic biology of
the cells as well as their interactions with HIV.
Most prior studies have demonstrated an  two- to six-
fold increase of T cell proliferation in untreated HIV-
infected patients compared with uninfected patients (6–10,
14). In the majority of them there was no relationship be-
tween viral load and proliferation. Methodological differ-
ences may help explain these discrepancies. Ki67 staining,
for example, provides only a snapshot of proliferating cells,
but does not allow the longitudinal observation of individ-
ual cells to use for development of kinetic models that is
provided by BrdU labeling. Moreover, Ki67 staining is not
limited to proliferating cells (30). In the current study there
was a good correlation between peak labeling and Ki67
staining for both CD4 and CD8 cells, consistent with the
concept that proliferation (as measured by BrdU incorpora-
tion) occurs primarily in activated (Ki67 positive) cells.
Lack of an even better correlation between the two meth-
ods may be related to the observation that in HIV infec-
tion, Ki67 staining includes a high proportion of effector
cells that have accumulated in G1 as well as those undergo-
ing cell division (31). Published studies with deuterium la-
beling have not sampled with the frequency necessary to
delineate the decay kinetics described here, and may lack
the sensitivity to define the decay of the slowly proliferat-
ing subpopulation (9, 10). Pulse labeling with BrdU pro-
vides a method for longitudinally following a population of
cells with a sensitivity that permits detection of labeled cells
for months to years, and thus permits more accurate mod-
eling of the kinetics of these cells.
Despite the detailed characterization of cell kinetics pro-
vided by the BrdU methodology, the mechanisms leading
to the preferential decline of CD4 counts seen in patients
with HIV infection remain obscure. In contrast to other
studies, our data provide no evidence for decreased pro-
duction as a major pathogenic mechanism in CD4 T cell
depletion (7, 9, 10). Given that the loss of CD4 cells oc-
curs gradually over a period of years, the kinetic differ-
ences in decay rates between CD4 and CD8 cells may be
too subtle to measure using currently available methodolo-
gies, or may require information from a larger cohort of
patients. It is clear that both cell types have increased pro-
liferation and decay rates due to a relative increase in the
size of the rapidly proliferating subpopulation of cells. Dif-
ferences in the biology of the cells in response to activa-
tion, or infection of CD4 but not CD8 cells by HIV may
shift the balance in CD4 cells to favor gradual depletion of
this population.
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